In keeping with Masimo’s mission to improve patient care, and to help clinicians separate fact from fiction, Masimo is renewing and expanding its performance guarantee. If Masimo SET is proven not to be more accurate than all Nellcor™ pulse oximeters, including the three that Covidien recently announced have received FDA 510(k) clearance with motion claims1,2, we will pay up to $1,000,000 to help your hospital acquire that pulse oximetry.
Masimo SET technology has been clinically proven in more than 100 independent studies to be the most accurate pulse oximetry under the most challenging conditions of motion and low perfusion and when it's needed the most. These studies have shown significant improvements in false alarm rejection, true alarm detection, drop outs (failure to operate), and accuracy, as well as cost savings from fewer blood gases, decreased oxygen usage and improved sensor longevity.
Our goal is to offer assistance to clinicians, biomedical engineers, and administrators who are interested in improving their pulse oximetry monitoring performance by providing a vehicle to secure objective evaluations in their hospital. Only serious inquiries will be accepted, as our common goal must be to improve the hospital-wide performance of your pulse oximetry technology. We understand that hospital conversions to a new technology and platform require time and effort, but we are so confident in the performance of Masimo SET technology that we are willing to guarantee that your time and effort will not be wasted.
Important details, conditions and qualifications:
- You must register by contacting Masimo Corporation at 1-877-4-MASIMO (1-877-462-7466). After you register, we will contact you to determine your hospital's eligibility. A contract must be signed between Masimo Corporation and the hospital facility prior to proceeding. Prior to commencement, the parties will agree to terms for the hospital to acquire and convert the entire facility to Masimo SET V7 pulse oximetry. To qualify, a commitment for at least 250 Masimo SET V7 equipped devices must be made.
- Clinical protocols for comparatively assessing and automatically documenting performance from both devices will be agreed upon by both parties prior to commencement and must be adhered to throughout the evaluation. Masimo participants must have unlimited access to hospital facility during the evaluation period. Only Nellcor OxiMax/N-600x pulse oximetry technology is eligible to be compared for this evaluation.
- If Masimo SET outperforms Nellcor in the evaluation during motion artifact and low perfusion, the hospital will complete the agreed upon purchase within 60 days from the end of the evaluation period. If Nellcor OxiMax/N-600x outperforms Masimo SET in the evaluation during motion artifact and low perfusion, Masimo will pay the hospital up to $1,000,000 towards a hospital-wide conversion to the product that was used in the evaluation. To be eligible for the award, the hospital must complete this conversion within 60 days.
- Nothing said or written anywhere else shall supersede the contract. Masimo reserves the right to change the conditions for this offer or withdraw this offer at any time without notice. This offer is available worldwide and is void where prohibited by law.